SGLT2 Inhibitors: Emerging Opportunities for the Treatment of Myocardial Infarction

Sodium-glucose co-transporter 2 inhibitors (SGLT2i) have shown promising cardiorenal benefits, especially in diabetic patients with severe kidney disease, heart failure (HF), or a history of myocardial infarction (MI). Drugs like empagliflozin, canagliflozin, and dapagliflozin reduce mortality risk in these groups, particularly for those with chronic HF and reduced ejection fraction. SGLT2i is under extensive investigation, with around 29 clinical trials exploring its role in MI, including ongoing Phase II-IV studies. Findings suggest that SGLT2i may prevent adverse cardiac remodeling, chronic HF, and cardiac mortality post-MI, addressing unmet therapeutic needs in high-risk patients. The possibility of initiating SGLT2i treatment shortly after an acute MI is also being explored and could transform MI management if proven effective. These investigations support SGLT2i as a potentially new cohort of cardiorenal-protective drugs comparable to traditional RAAS inhibitors, marking a paradigm shift in cardiovascular care.